Bicycle Therapeutics GAAP EPS of -$0.15 beats by $0.33, revenue of $34.06M beats by $21.86M (BCYC:NASDAQ)
Bicycle Therapeutics (BCYC) reported Q3 GAAP EPS of -$0.15, beating estimates by $0.33. Revenue was $34.06M, up 190.4% Y/Y and exceeding expectations by $21.86M. The company is shifting focus from Zelenectide to EphA2+ tumor targeting.
How this was made
The 30-second read
Why it matters
The earnings beat could trigger short‑term buying, but investors will watch cash runway and upcoming trial data.
Market read
Earnings surprise provides a fresh catalyst for BCYC, with potential short‑term price upside.
What to watch
Future guidance was not provided; sustainability of growth remains uncertain.
Background
Bicycle Therapeutics released its Q3 2026 earnings, reporting a GAAP loss per share and a large year‑over‑year revenue increase.
Ticker impact
Q3 GAAP EPS of -$0.15 beats expectations by $0.33 and revenue of $34.06M beats by $21.86M, first report of the earnings results.
likely upward pressure as the market prices in the earnings beat
Both EPS and revenue significantly exceeded expectations, which typically drives short-term buying interest.
Market effects
Positive earnings may lift sentiment in the biotech/oncology sector.
Limited to US biotech investors.
Low; impact confined to niche biotech investors.
Counterpoint
Despite the beat, the company remains loss-making and may face cash‑burn concerns.
Key entities
- companyBicycle Therapeutics
NASDAQ‑listed biotech focused on peptide therapeutics.
